BIOMARIN PHARMACEUTICAL INC Quarterly Deferred Income Tax Assets, Net in USD from Q4 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
Summary
Biomarin Pharmaceutical Inc quarterly Deferred Income Tax Assets, Net history and growth rate from Q4 2018 to Q3 2024.
  • Biomarin Pharmaceutical Inc Deferred Income Tax Assets, Net for the quarter ending September 30, 2024 was $1.53B, a 0.45% increase year-over-year.
Deferred Income Tax Assets, Net, Quarterly (USD)
Deferred Income Tax Assets, Net, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $1.53B +$6.83M +0.45% Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $1.55B +$35.7M +2.37% Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $1.55B +$35.5M +2.35% Mar 31, 2024 10-Q 2024-04-26
Q4 2023 $1.55B +$40.4M +2.68% Dec 31, 2023 10-Q 2024-10-31
Q3 2023 $1.52B +$68.7M +4.72% Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $1.51B +$60.4M +4.17% Jun 30, 2023 10-Q 2023-08-02
Q1 2023 $1.51B +$63.9M +4.42% Mar 31, 2023 10-Q 2023-04-28
Q4 2022 $1.51B +$55.3M +3.81% Dec 31, 2022 10-K 2024-02-26
Q3 2022 $1.46B +$10.1M +0.7% Sep 30, 2022 10-Q 2022-10-28
Q2 2022 $1.45B +$17.2M +1.2% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $1.45B +$17.3M +1.21% Mar 31, 2022 10-Q 2022-04-29
Q4 2021 $1.45B +$18M +1.26% Dec 31, 2021 10-K 2023-02-27
Q3 2021 $1.45B +$48.6M +3.48% Sep 30, 2021 10-Q 2021-10-29
Q2 2021 $1.43B +$877M +158% Jun 30, 2021 10-Q 2021-07-30
Q1 2021 $1.43B +$889M +165% Mar 31, 2021 10-Q 2021-04-30
Q4 2020 $1.43B +$883M +161% Dec 31, 2020 10-K 2022-02-25
Q3 2020 $1.4B +$871M +166% Sep 30, 2020 10-Q 2020-11-06
Q2 2020 $555M Jun 30, 2020 10-Q 2020-08-05
Q1 2020 $540M Mar 31, 2020 10-Q 2020-05-01
Q4 2019 $549M +$88.5M +19.2% Dec 31, 2019 10-K 2021-02-26
Q3 2019 $525M Sep 30, 2019 10-Q/A 2019-11-04
Q4 2018 $461M Dec 31, 2018 10-K 2020-02-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.